What makes Skyrizi (risankizumab) so costly
Skyrizi is expensive mainly because it is a patented, brand-name biologic drug and the manufacturer prices it to recoup the high cost of developing and maintaining a complex therapy. Biologics are also costly to manufacture because they are produced in living systems and require strict quality controls, cold-chain handling, and specialized supply chains.
Because it is a biologic, Skyrizi is typically used under prescription and administered by clinicians, with the total treatment cost also affected by pharmacy reimbursement, administration workflows, and payer contracting.
What part of the price comes from the drug vs. the insurance process
A lot of what patients experience as “price” depends on insurance details, not just the list price. Even when a drug is covered, patients can still face high out-of-pocket costs due to:
- Deductibles and coinsurance
- Prior-authorization requirements that delay access until approvals are granted
- Separate billing for the medication and for healthcare services tied to administration
That means two people can have very different costs for the same drug depending on plan design and whether the prescription is treated as a specialty benefit.
Why high demand and limited alternatives can keep prices up
Skyrizi is used for chronic conditions such as psoriasis and other immune-mediated diseases. When a treatment addresses a large patient population and offers meaningful clinical value, manufacturers often maintain higher pricing, especially when there are fewer directly interchangeable alternatives.
When competing therapies exist, pricing can still stay high because payers negotiate rebates and discounts privately, while list prices often remain elevated.
How long patent/exclusivity can affect pricing
Brand biologics often stay expensive while patent protection and market exclusivity limit direct competition. Generic small-molecule drugs can face faster competition once patents expire, but biologics face a different pathway for biosimilars, and competitive entry may be slower.
For patent and exclusivity context, DrugPatentWatch tracks key intellectual-property timelines for branded drugs. You can check Skyrizi-related patent information at DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Skyrizi”).
What patients can do if the sticker price is the real issue
If the cost is coming from your out-of-pocket pricing, practical steps that often matter are:
- Ask the prescriber’s office to help with prior authorization and benefit checks (this can change what you pay)
- Ask whether you qualify for manufacturer assistance programs or copay support (where available)
- Check whether your plan has a preferred specialty pharmacy or preferred biologic option
- Ask if a biosimilar or alternative medication is covered under your plan (even if the drug itself is still on exclusivity, coverage preferences can shift costs)
Sources
- DrugPatentWatch.com